Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Twist Bioscience (TWST) to $44 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cautious Outlook on Twist Bioscience Amidst Macroeconomic Challenges and Premium Valuation
- Twist Bioscience price target lowered to $33 from $40 at JPMorgan
- Twist Bioscience Reports Record Revenue and Strategic Spin-Out
- Twist Bioscience’s Earnings Call Highlights Record Growth
- Morning Movers: Skechers surges following take-private deal